Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2024-03-05
2035-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Project 1 Aim 2 and 3
NCT03079037
Udall Project 2 Aim 2A&C
NCT05656586
Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease
NCT05557864
Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Clinical Core
NCT03021031
Basal Ganglia Local Field Potentials in Gait and Speech
NCT01905995
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients will make one visit to the M Health Clinical Research Unit (CRU) after overnight withdrawal of PD medications (still on-DBS) and undergo motor and cognitive assessments in the following three conditions:
1. clinically-optimized stimulation
2. model-based stimulation directed towards motor subregions of STN and GPi
3. model-based stimulation directed towards associative/limbic subregions of STN/GPi
Randomized to start with condition1 assessment
No interventions assigned to this group
Group 2
Patients will make one visit to the M Health Clinical Research Unit (CRU) after overnight withdrawal of PD medications (still on-DBS) and undergo motor and cognitive assessments in the following three conditions:
1. clinically-optimized stimulation
2. model-based stimulation directed towards motor subregions of STN and GPi
3. model-based stimulation directed towards associative/limbic subregions of STN/GPi
Randomized to start with condition 2 assessment
No interventions assigned to this group
Group 3
Patients will make one visit to the M Health Clinical Research Unit (CRU) after overnight withdrawal of PD medications (still on-DBS) and undergo motor and cognitive assessments in the following three conditions:
1. clinically-optimized stimulation
2. model-based stimulation directed towards motor subregions of STN and GPi
3. model-based stimulation directed towards associative/limbic subregions of STN/GPi
Randomized to start with condition 3 assessment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Existing 7T imagery (either done as standard-of-care or done as part of Noam Harel's study, IRB #1210M22183)
* Diagnosed with idiopathic Parkinson's Disease
* Minimum age 21 years
Exclusion Criteria
* Diagnosis of dementia
* Pregnant
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerrold Vitek, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00007781
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.